Exome sequencing of 20,791 cases of type 2 diabetes and 24,440 controls

Show full item record



Permalink

http://hdl.handle.net/10138/304025

Citation

Broad Genomics Platform , DiscovEHR Collaboration , CHARGE , LuCamp , ProDiGY , GoT2D , ESP , SIGMA-T2D , T2D-GENES , AMP-T2D-GENES , Flannick , J , Mercader , J M , Koistinen , H A , Kuusisto , J , Groop , L , Tuomi , T , Tuomilehto , J & Boehnke , M 2019 , ' Exome sequencing of 20,791 cases of type 2 diabetes and 24,440 controls ' , Nature , vol. 570 , no. 7759 , pp. 71-+ . https://doi.org/10.1038/s41586-019-1231-2

Title: Exome sequencing of 20,791 cases of type 2 diabetes and 24,440 controls
Author: Broad Genomics Platform; DiscovEHR Collaboration; CHARGE; LuCamp; ProDiGY; GoT2D; ESP; SIGMA-T2D; T2D-GENES; AMP-T2D-GENES; Flannick, Jason; Mercader, Josep M.; Koistinen, Heikki A.; Kuusisto, Johanna; Groop, Leif; Tuomi, Tiinamaija; Tuomilehto, Jaakko; Boehnke, Michael
Contributor: University of Helsinki, HUS Internal Medicine and Rehabilitation
University of Helsinki, Centre of Excellence in Complex Disease Genetics
University of Helsinki, Centre of Excellence in Complex Disease Genetics
University of Helsinki, National Institute for Health and Welfare (THL)
Date: 2019-06-06
Language: eng
Number of pages: 24
Belongs to series: Nature
ISSN: 0028-0836
URI: http://hdl.handle.net/10138/304025
Abstract: Protein-coding genetic variants that strongly affect disease risk can yield relevant clues to disease pathogenesis. Here we report exome-sequencing analyses of 20,791 individuals with type 2 diabetes (T2D) and 24,440 non-diabetic control participants from 5 ancestries. We identify gene-level associations of rare variants (with minor allele frequencies of less than 0.5%) in 4 genes at exome-wide significance, including a series of more than 30 SLC30A8 alleles that conveys protection against T2D, and in 12 gene sets, including those corresponding to T2D drug targets (P = 6.1 x 10(-3)) and candidate genes from knockout mice (P = 5.2 x 10(-3)). Within our study, the strongest T2D gene-level signals for rare variants explain at most 25% of the heritability of the strongest common single-variant signals, and the gene-level effect sizes of the rare variants that we observed in established T2D drug targets will require 75,000-185,000 sequenced cases to achieve exome-wide significance. We propose a method to interpret these modest rare-variant associations and to incorporate these associations into future target or gene prioritization efforts.
Subject: GENOME-WIDE ASSOCIATION
COMMON GENETIC-VARIATION
LOW-FREQUENCY
RARE VARIANTS
MUTATIONS
RISK
IDENTIFICATION
HERITABILITY
ARCHITECTURE
METAANALYSIS
3121 General medicine, internal medicine and other clinical medicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
s41586_019_1231_2.pdf 8.569Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record